November 29, 2012 | Thursday | Opinion | By BioSpectrum Bureau
Dr G-Halli Rajasekariah, chief scientist and Dr Hubert G Mazure, marketing manager- Cellabs, Australia
Would patent expiry of major monoclonal antibodies (mAbs) impact the pharma market soon?